J Clin Neurol.  2018 Oct;14(4):583-585. 10.3988/jcn.2018.14.4.583.

Safe Childbirth after Taking Teriflunomide in a Woman with Multiple Sclerosis

Affiliations
  • 1Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  • 2Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. nrshlee@chonnam.ac.kr

Abstract

No abstract available.


MeSH Terms

Female
Humans
Multiple Sclerosis*
Parturition*

Figure

  • Fig. 1 MRI scans of the patient. Initial brain MRIs show multiple HSILs in the pons, middle cerebellar peduncle, subcortical and periventricular white matter on the FLAIR imaging (A) and gadolinium-enhancement imaging (B). B: The optic nerves are enhanced bilaterally. C: Three months after administration of teriflunomide, follow-up FLAIR images show resolution of previous HSILs. D: The spine MRIs show eccentric HSILs in the thoracic (arrows) and the cervical spinal cord (open arrow). HSILs: high signal intensity lesions.


Reference

1. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013; 19:835–843.
Article
2. Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016; 15:292–303.
Article
3. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69:292–302.
Article
4. Vukusic S, Coyle PK, Jurgensen S, Truffinet P, Benamor M, Poole E, et al. Pregnancy outcomes in patients with MS treated with teriflunomide: clinical study and postmarketing data. Neurology. 2018; 90:15 supplement. P4.361.
5. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13:247–256.
Article
6. Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014; 3:133–138.
Article
7. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol. 1999; 37:731–751.
Full Text Links
  • JCN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr